Skip to Content
Merck
CN

SML0042

Lazabemide hydrate

≥97% (HPLC)

Synonym(s):

N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C8H10ClN3O · xH2O
CAS Number:
Molecular Weight:
199.64 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2

SMILES string

O.NCCNC(=O)c1ccc(Cl)cn1

InChI key

JYWYNPKXSLPWGV-UHFFFAOYSA-N

assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to tan

solubility

DMSO: ≥22 mg/mL

originator

Roche

storage temp.

room temp

Quality Level

Application

Lazabemide hydrate may be used in cell signaling studies.

Biochem/physiol Actions

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease and in combination with nicotine replacement therapy aids in smoking cessation.
Selective MAO-B inhibitor; Antiparkinson

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ivan Berlin et al.
Addiction (Abingdon, England), 97(10), 1347-1354 (2002-10-03)
Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is probably due to some components of tobacco smoke. When smokers quit, MAOB activity returns to normal. Reduced MAO activity may increase nicotine's
R P Mason et al.
Biochemical pharmacology, 60(5), 709-716 (2000-08-06)
Free radical-induced damage to lipid and protein constituents of neuronal membranes contributes to the pathophysiology of neurodegenerative diseases, including Alzheimer's disease (AD). The development of an effective inhibitor of oxidative stress represents an important goal for the treatment of AD.
D H Fitzgerald et al.
Journal of neural transmission (Vienna, Austria : 1996), 109(3), 251-265 (2002-04-17)
The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and
N Andrés et al.
Neuroscience, 101(4), 807-810 (2000-12-13)
Aged rats may be behaviorally classified as either cognitively impaired or unimpaired based upon their performance in the Morris water maze task. In aged Long-Evans rats, emergence of functional deficits has been related to the increase in the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
Yuji Kitaichi et al.
European journal of pharmacology, 532(3), 236-245 (2006-02-21)
We investigated the effects of clorgyline [a selective MAO (monoamine oxidase inhibitor)-A inhibitor] and lazabemide (a selective MAO-B inhibitor) on extracellular serotonin, dopamine and noradrenaline concentrations in the medial prefrontal cortex after 1-week treatment with subchronic 0.2% or 0.05% Li2CO3

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service